Skip to main content
DNLI
NASDAQ Life Sciences

Denali Therapeutics Sells Rare Pediatric Disease Voucher for $195 Million

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$23.89
Mkt Cap
$3.728B
52W Low
$12.58
52W High
$24.205
52W Position info
90% above low
Off High info
1.3% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

DNLI sits 90% above its 52-week low of $12.58.

Summary

Denali Therapeutics Inc. has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in cash, significantly boosting its financial flexibility.


Key Events · Financing and Capital Events · DNLI

  • Sale of Priority Review Voucher

    Denali Therapeutics entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million in cash.

  • Non-Dilutive Capital Raise

    The $195 million in proceeds are non-dilutive and will be used to advance the company's broad clinical pipeline, including programs for lysosomal storage disorders and neurodegenerative diseases.

  • Monetization of Regulatory Success

    The PRV was awarded following the FDA accelerated approval of AVLAYAH™ (tividenofusp alfa-eknm) for Hunter syndrome in March 2026.


Analysis · DNLI · Life Sciences

This 8-K filing announces a substantial non-dilutive cash infusion for Denali Therapeutics, providing $195 million from the sale of a Rare Pediatric Disease Priority Review Voucher. This capital will support the advancement of its broad clinical pipeline, which is crucial for a biotech company, especially following the recent discontinuation of a Parkinson's drug. The sale monetizes a regulatory achievement (AVLAYAH™ approval) and strengthens the company's balance sheet without shareholder dilution, coming as the stock trades near its 52-week high.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DNLI was trading at $23.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $12.58 to $24.21. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DNLI - Latest Insights

DNLI
Nov 09, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $20.35
Real-time Price: $18.74 info
Change: -$1.61 (-8%) info
Market Cap: $3.004B info
DNLI
Nov 03, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $19.45
Real-time Price: $18.74 info
Change: -$0.710 (-4%) info
Market Cap: $3.004B info
DNLI
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $19.45
Real-time Price: $18.74 info
Change: -$0.710 (-4%) info
Market Cap: $3.004B info
DNLI
Aug 06, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $25.10
Real-time Price: $18.74 info
Change: -$6.36 (-25%) info
Market Cap: $3.004B info
DNLI
Jun 18, 2026, 8:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $23.89
Real-time Price: $18.74 info
Change: -$5.15 (-22%) info
Market Cap: $3.004B info